ELAGOLIX SODIUM
| Brand name | ORILISSA |
|---|---|
| Active ingredient | ELAGOLIX SODIUM |
| Strength | EQ 150MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2018 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11690845 | August 2040 | use U-3654 |
| 11542239 | July 2039 | substance, product |
| 12102637 | August 2038 | product |
| 11690854 | April 2038 | use U-3653 |
| 10682351 | September 2036 | use U-2850 |
| 10537572 | September 2036 | use U-2735 |
| 11707464 | March 2034 | use U-3672 |
| 7419983 | July 2029 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.